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Abstract
Background: Genetic polymorphisms in DNA repair genes may influence individual variation in DNA repair capacity, which
may be associated with risk of developing cancer. For colorectal cancer the importance of mutations in mismatch repair genes
has been extensively documented. Less is known about other DNA repair pathways in colorectal carcinogenesis. In this study
we have focused on the XRCC1, XRCC3 and XPD genes, involved in base excision repair, homologous recombinational repair
and nucleotide excision repair, respectively.
Methods: We used a case-control study design (157 carcinomas, 983 adenomas and 399 controls) to test the association
between five polymorphisms in these DNA repair genes (XRCC1 Arg194Trp, Arg280His, Arg399Gln, XRCC3 Thr241Met and XPD
Lys751Gln), and risk of colorectal adenomas and carcinomas in a Norwegian cohort. Odds ratio (OR) and 95% confidence
interval (95% CI) were estimated by binary logistic regression model adjusting for age, gender, cigarette smoking and alcohol
consumption.
Results: The XRCC1 280His allele was associated with an increased risk of adenomas (OR 2.30, 95% CI 1.19–4.46). The XRCC1
399Gln allele was associated with a reduction of risk of high-risk adenomas (OR 0.62, 95% CI 0.41–0.96). Carriers of the variant
XPD 751Gln allele had an increased risk of low-risk adenomas (OR 1.40, 95% CI 1.03–1.89), while no association was found with
risk of carcinomas.
Conclusion: Our results suggest an increased risk for advanced colorectal neoplasia in individuals with the XRCC1 Arg280His
polymorphism and a reduced risk associated with the XRCC1 Arg399Gln polymorphism. Interestingly, individuals with the XPD
Lys751Gln polymorphism had an increased risk of low-risk adenomas. This may suggest a role in regression of adenomas.
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In Western populations the vast majorities of colorectal
cancers (CRC) arise from benign adenomatous polyps
(colorectal adenomas) and evolve through the adenoma-
carcinoma sequence, a multistep process of genetic altera-
tions [1,2]. The lifetime risk of CRC in a normal popula-
tion is low in comparison to the prevalence of adenomas.
This indicates that only a few of the adenomas will
develop into a carcinoma. However, from the perspective
of understanding the genetic events involved in colonic
neoplasia, these early lesions are valuable endpoints.
The risk of sporadic CRC is associated with lifestyle factors
like cigarette smoking and alcohol consumption which
may be modulated by several genetic factors of low pene-
trance [3,4]. Cigarette smoke and alcohol may act as
sources of chemical carcinogens (including nitrosamines,
heterocyclic amines and polycyclic hydrocarbons), reac-
tive oxygen species (ROS) [5,6] and DNA adduct forma-
tion [3]. Genetic polymorphisms in DNA repair genes
may influence individual variation in DNA repair capac-
ity, which may be associated with risk of developing can-
cer [7]. During the past years, an increasing number of
DNA repair gene polymorphisms have been described
and their involvement in carcinogenesis investigated. For
colorectal cancer, the importance of mutations in mis-
match repair (MMR) genes has been extensively docu-
mented. Less is known about other DNA repair pathways
in colorectal carcinogenesis, and in this study we have
focused on the XRCC1, XRCC3 and XPD genes.
The DNA repair gene XRCC1 gene codes for a protein
involved in the repair of single-strand breaks (SSB) and in
base excision repair (BER) of damaged bases caused by
endogenous and exogenous oxidants. Three polymor-
phisms occurring at conserved sequences in the XRCC1
gene were reported by Shen et al. [8]. These coding poly-
morphisms, resulting in amino acid substitutions, were
detected at codons 194 (Arg-Trp), 280 (Arg-His) and 399
(Arg-Gln). Most studies report a reduced risk of cancer
associated with the 194Trp allele [9]. The 399 polymor-
phism have been associated with a number of cancers,
although results have been inconsistent [9-15]. Few stud-
ies have investigated the association between the XRCC1
280His allele and risk of cancer. No association has been
observed with colorectal cancer [13], but an increased risk
has been reported with lung cancer [16] and breast cancer
[17].
The XRCC3 gene codes for a protein involved in homolo-
gous recombinational repair (HRR) of double-strand
DNA and is required for genomic stability [18,19]. The
XRCC3 gene has a sequence variation in exon 7
(C18067T), which results in an amino acid substitution at
codon 241 (Thr241Met) that may affect the enzyme's func-
tion and/or its interaction with other proteins involved in
DNA damage and repair [20]. Molecular epidemiological
studies have linked this XRCC3 polymorphism to
increased risk of breast cancer [21], lung cancer [22], skin
cancer [23] and colorectal cancer [14]. The results have
been inconsistent [24].
The XPD protein is involved in the nucleotide excision
repair (NER) pathway [25], which recognizes and repairs
a wide range of structurally unrelated lesions such as
bulky adducts and thymidine dimers [26-28]. The XPD
gene encodes a helicase that is a component of the tran-
scription factor TFIIH [29]. Mutations in the XPD gene can
diminish the activity of TFIIH complexes increasing the
likelihood of repair defects, transcription defects, and
abnormal responses to apoptosis [30]. The XPD Lys751Gln
substitution is attributed to a (A→C) transversion at exon
23 [8]. Several epidemiological studies have investigated
the association between XPD polymorphisms and cancer.
Smoking related cancers and skin cancers are most fre-
quently investigated, but it is not yet established whether
the polymorphism is linked to risk of lung cancer [31,32].
No association has been observed with the various stages
of the adenoma-carcinoma sequence or with colorectal
cancer [14,15].
In the present study we used a case-control design to test
the association between five amino acid substitution var-
iants of DNA repair genes, XRCC1 (Arg194Trp), XRCC1
(Arg280His), XRCC1 (Arg399Gln), XRCC3 (Thr241Met) and
XPD (Lys751Gln), and colorectal adenoma/cancer risk in a
Norwegian cohort. The main focus was to investigate if
these polymorphisms are linked to risk of colorectal ade-
noma and carcinoma. By studying repair genes in the var-
ious stages of the adenoma-carcinoma sequence we may
gain new information on the significance of polymor-
phisms in neoplastic tissues during transition.
Methods
The cohort in the KAM (Kolorektal cancer, Arv og Miljø)
molecular epidemiological study is based on the screen-
ing group of the Norwegian Colorectal Cancer Prevention
study (The NORCCAP study) in the county of Telemark
[33]. The ID number for the NORCCAP study at Clinical-
Trials.gov is NCT00119912 [34]. In addition, patients
diagnosed with colorectal cancer, operated on at Telemark
Hospital (Skien) and Ulleval University Hospital (Oslo)
were included. The KAM cohort is based on an ethnic
homogeneous group of Norwegian origin.
The KAM biobank consists of blood and tissue samples
from 1044 individuals identified with adenomas in the
large intestine (991 high- and low-risk adenomas, 53
hyperplastic polyps), 160 with colorectal cancer and 400
controls, defined as individuals with normal findings atPage 2 of 9
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completed a questionnaire on demographics, health sta-
tus, dietary; and smoking habits, alcohol consumption,
physical exercise and occupation. The questionnaire con-
tained information on a family history of adenomas and
carcinomas, and the included cases and controls had no
known personal history of genetic predisposition. The
KAM study is approved by the Regional Ethics Committee
and the Data Inspectorate.
In the present study we analyzed available blood samples
from 157 cases with carcinoma, 983 cases with adenomas,
(i.e. 227 high-risk and 756 low-risk adenomas) and 399
controls. A high-risk adenoma is defined as an adenoma
measuring ≥ 10 mm in diameter and/or with villous com-
ponents and/or showing severe dysplasia [33].
The distribution of age, gender, cigarette smoking and
alcohol consumption among controls and cases with
colonic carcinomas and adenomas are shown in Table 1.
Table 1: Distributions of age, gender, cigarette smoking and alcohol consumption among controls and cases with colorectal 
carcinomas and adenomas.
Controls Carcinomas Adenomas, all High-risk 
adenomas
Low-risk adenomas
No (%) No (%) No (%) No (%) No (%)
No. of subjects 399 157 983 227 756
Gendera
Male 157 (39.3) 87 (55.4) 603 (61.3) 150 (66.1) 453 (59.9)
Female 242 (60.7) 70 (44.6) 380 (38.7) 77 (33.9) 303 (40.1)
Ageb
Mean (SD) 54.2 (3.3) 67.9 (11.2) 57.3 (3.7) 57.3 (3.5) 57.3 (3.8)
Smoking status * 
Never smoked 155 (46.7) 33(31.1) 253 (30.6) 51 (27.0) 202 (31.7)
Ever smoked 177 (53.3) 73 (68.9) 574 (69.4) 138 (73.0) 436 (68.3)
Mean no. of cigarette 
years (SD)
249(229) 383(339) 360(263) 389(244) 351(269)
Alcohol consumption * 
< 1 unit/month 72 (21.7) 36 (34.0) 180 (21.8) 43 (22.8) 137 (21.5)
≥ 1 unit/month 260 (78.3) 70 (66.0) 647 (78.2) 146 (77.2) 501 (78.5)
Mean units of alcohol 
per month (SD)
11.1 (12.2) 15.5 (22.3) 16.4 (22.9) 18.4 (29.8) 15.8 (20.4)
* Missing values for cigarette smoking and alcohol consumption gave rise to diminished number of cases and controls.
a There are significant differences in the number of males and females in the control group and the case groups, p < 10-4 (test for comparison of two 
proportions).
b There are significant differences in age among the control group and the case groups, p < 10-4 (Mann-Whitney test).
Table 2: Design of primers and TaqMan probes for allelic discrimination assay.
Primer /Probe Sequence
XRCC1 codon 194
Forward primer: 5'-GAG GAT GAG AGC GCC AAC TC-3'
Reverse primer: 5'-TCA CTC AGG ACC CAC GTT GTC-3'
Probe C allele: 5'-VIC-TCT TCA GCC GGA TCA-MGB/NFQ-3'
Probe T allele: 5'-FAM-TCT TCA GCTGGA TCA A-MGB/NFQ-3'
XRCC1 codon 280
Forward primer: 5'-GGT GCT AAC CTA ATC TAC TCT TTG TCT TC-3'
Reverse primer: 5'-TGG GCT CGG TGC CTT CT-3'
Probe G allele: 5'-VIC-AGC TCC AAC TCG TAC C-MGB/NFQ-3'
Probe A allele: 5'-FAM-AGC TCC AAC TCA TAC C-MGB/NFQ-3'
XRCC1 codon 399
Forward primer: 5'-GAG TGG GTG CTG GAC TGT CA-3'
Reverse primer: 5'-CAT TGC CCA GCA CAG GAT AA-3'
Probe G allele: 5'-VIC-CCT CCC GGA GGT AA-MGB/NFQ-3'
Probe A allele: 5'-FAM-CCT CCC AGA GGT AAG-MGB/NFQ-3'
The bold underlined letters represent the polymorphic positions.Page 3 of 9
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ing to standard procedures [35] with minor modifica-
tions. In brief, whole blood samples (anticoagulated) was
mixed with a threefold volume of lysis buffer (155 mM
NH4Cl, 10 mM KHCO3, 1 mM EDTA pH 7.4) and incu-
bated at 4°C for at least 30 min. The lysate was then cen-
trifuged, and pellet of intact leukocytes was resuspended
in 10 ml SE buffer (75 mM NaCl, 24 mM EDTA pH 8.0)
500 µl SDS (20 %) and 50 µl Proteinase K (20 mg/ml) and
incubated overnight at 40°C. After digestion, 3.5 ml 6 M
NaCl was added to the lysate and the mixture was shaken
vigorously and then centrifuged to pellet the cellular pro-
teins. DNA in the supernatant was then precipitated with
2 volumes of absolute ethanol, washed in 70 % ethanol
and resuspended in TE buffer (10 mM TrisHCl, 0.1 mM
EDTA, pH 7.5).
Genotype analysis of the five single nucleotide polymor-
phisms (SNPs) of the DNA repair genes XRCC1, XRCC3
and XPD was carried out using the TaqMan allelic discrim-
ination assay on a Sequence Detection System ABI 7000
(Applied Biosystems). The XRCC1 polymorphisms
(XRCC1 Arg194Trp (rs#1799782), XRCC1 Arg280His
(rs#25489), XRCC1 Arg399Gln (rs#25487)) were deter-
mined in 12 µl reactions containing 1× MasterMix, 200
nM of each probe, 900 nM primers, and 50–100 ng of
genomic DNA. Cycling conditions were as follows: 50°C
for 2 min, 95°C for 10 min, and 45 cycles of 95°C for 15
s and 60°C for 1 min. Primers and probes are described in
Table 2. The XRCC3 Thr241Met (rs#861539) and XPD
Lys751Gln (rs#1052559) were genotyped as described pre-
viously [24,36]. Controls were included in each run and
repeated genotyping of a random 10 % subset yielded 100
% identical genotypes.
SPSS (Statistical Packages for the Social Sciences) 12.0.1
for Windows was used for the statistic calculations. Odds
ratios (OR) and 95 % confidence intervals (CI) were cal-
culated using binary logistic regression to assess the rela-
tionship between each polymorphism and the colorectal
adenoma or carcinoma cases. Two separate ORs were cal-
culated, one adjusted for age only (Table 3), and the other
for age, gender, cigarette smoking (number of cigarette
years) and alcohol consumption (units of alcohol per
month) (Table 4). Due to missing data on cigarette smok-
ing and alcohol consumption (67 controls, 51 carcinomas
Table 3: Distributions of XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XRCC3 Thr241Met and XPD Lys751Gln genotypes and 
development of colorectal carcinomas and adenomas. ORs are adjusted for age.
Genotypes Controls Carcinomas OR (95% CI) Adenomas OR (95% CI) High-risk 
adenoma
s
OR (95% CI) Low-risk 
adenomas
OR (95% CI)
XRCC1 Arg194Trp
Arg/Arg (CC) 352 135 1a 864 1a 197 1a 667 1a
Arg/Trp (CT) 46 19 0.99 (0.42–2.33) 115 1.07 (0.72–1.58) 29 1.35 (0.78–2.32) 86 0.99 (0.66–1.50)
Trp/Trp (TT) 1 2 - 4 - 1 - 3 -
Arg/Trp + Trp/Trp 47 21 1.00 (0.43–2.32) 119 1.09 (0.74–1.60) 30 1.38 (0.81–2.36) 89 1.01 (0.68–1.52)
Missing 1
XRCC1Arg280His
Arg/Arg (GG) 381 145 1a 906 1a 207 1a 699 1a
Arg/His (GA) 18 12 1.72 (0.58–5.04) 77 1.68 (0.96–2.93) 20 2.25 (1.10–4.60) 57 1.55 (0.87–2.76)
His/His (AA) 0 0 - 0 - 0 - 0 -
XRCC1Arg399Gln
Arg/Arg (GG) 148 63 1a 391 1a 100 1a 291 1a
Arg/Gln (GA) 187 70 0.74 (0.41–1.33) 443 0.82 (0.62–1.08) 95 0.67 (0.46–0.99) 348 0.87 (0.65–1.16)
Gln/Gln (AA) 64 24 0.91 (0.42–1.98) 149 0.88 (0.61–1.29) 32 0.65 (0.38–1.13) 117 0.96 (0.65–1.42)
Arg/Gln + Gln/Gln 251 94 0.78 (0.45–1.35) 592 0.84 (0.64–1.08) 127 0.67 (0.46–0.96) 465 0.90 (0.68–1.17)
XRCC3 Thr241Met
Thr/Thr (CC) 138 64 1a 380 1a 88 1a 292 1a
Thr/Met (CT) 201 73 1.15 (0.64–2.08) 456 0.83 (0.63–1.10) 109 0.86 (0.58–1.27) 347 0.81 (0.61–1.09)
Met/Met (TT) 60 20 1.09 (0.46–2.55) 147 0.92 (0.63–1.35) 30 0.84 (0.48–1.47) 117 0.97 (0.65–1.45)
Thr/Met + Met/Met 261 93 1.14 (0.64–2.01) 603 1.11 (0.23–0.85) 139 0.86 (0.59–1.24) 464 0.85 (0.65–1.12)
XPD Lys751Gln
Lys/Lys (AA) 175 58 1a 364 1a 87 1a 277 1a
Lys/Gln (AC) 173 76 0.92 (0.52–1.63) 463 1.36 (1.03–1.78) 100 1.11 (0.75–1.63) 363 1.43 (1.07–1.89)
Gln/Gln (CC) 50 22 0.84 (0.36–1.95) 155 1.55 (1.05–2.30) 40 1.38 (0.80–2.37) 115 1.56 (1.03–2.36)
Lys/Gln + Gln/Gln 223 98 0.90 (0.52–1.54) 618 1.40 (1.08–1.81) 140 1.17 (0.81–1.68) 478 1.46 (1.11–1.90)
Missing 1 1 1 1
a The genotype served as reference categoryPage 4 of 9
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to calculate OR adjusted for age, gender, cigarette smoking
and alcohol consumption (in Table 4) is reduced. Possi-
ble combined effects of the XRCC1 Arg280His and XRCC1
Arg399Gln polymorphisms were investigated in a two by
three table (Table 5).
Given the allele frequency of polymorphism of the con-
trols and assuming Hardy-Weinberg equilibrium, we had
a 65 % chance (at the 5 % level) of detecting an OR of 2.25
for XRCC1 codon 280 heterozygotes among high-risk
adenomas and 81 % among low-risk adenomas. We had
60 % chance of detecting an OR of 0.65 among carriers of
the variant allele of XRCC1 codon 399 among high-risk
adenomas and 81 % among low-risk adenomas. For the
XPD codon 751 polymorphism, we had 54 % chance of
detecting an OR of 1.36 and 1.55 among heterozygote
and homozygote carriers among high-risk adenomas and
79 % power among low-risk adenomas.
Haplotypes were estimated and ORs calculated using the
Hplus program available online [37]. Hplus is a SNP anal-
ysis tool for performing haplotype estimation according
to the distribution of genotypes in a population. Such
haplotype-based methods should be used either for mul-
tiple SNPs within candidate genes or when selected SNPs
are physically closed to each other [38]. We used this
method to estimate haplotypes of three SNPs within the
XRCC1 gene.
Results
The genotypic distributions of the five polymorphisms in
the three DNA repair genes for both cases and controls are
shown in Table 3. The frequencies for the XRCC1 194Trp
allele, XRCC1 280His allele, XRCC1 399Gln allele,
XRCC3 241Met allele and XPD 751Gln allele among the
controls were respectively, 0.06, 0.02, 0.39, 0.40 and 0.34.
The genotype distributions were all in Hardy-Weinberg
equilibrium and the distributions of the alleles in the con-
trol group are in agreement with those found in other
Caucasian populations [9], and in other Scandinavian
populations for the XRCC3 241Met allele and XPD
751Gln allele [24,36]. Tables 3 and 4 also presents the
estimates of ORs of colorectal adenomas and carcinomas
associated with the various XRCC1, XRCC3 and XPD pol-
ymorphisms.
Table 4: Distributions of XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XRCC3 Thr241Met and XPD Lys751Gln genotypes and 
development of colorectal carcinomas and adenomas. ORs are adjusted for age, gender, cigarette smoking and alcohol consumption.
Genotypes Controls Carcinomas OR (95% CI) Adenomas OR (95% CI) High-risk 
adenomas
OR (95% CI) Low-risk 
adenomas
OR (95% CI)
XRCC1 Arg194Trp
Arg/Arg (CC) 292 92 1a 734 1a 166 1a 568 1a
Arg/Trp (CT) 39 11 0.82 (0.27–2.47) 89 0.95 (0.61–1.48) 22 1.37 (0.72–2.60) 67 0.85 (0.53–1.36)
Trp/Trp (TT) 1 2 - 4 - 1 - 3 -
Arg/Trp + Trp/Trp 40 13 0.84 (0.28–2.48) 93 0.96 (0.62–1.49) 23 1.35 (0.71–2.56) 70 0.87 (0.55–1.38)
Missing 1
XRCC1Arg280His
Arg/Arg (GG) 319 100 1a 764 1a 174 1a 590 1a
Arg/His (GA) 13 6 1.48 (0.29–7.48) 63 2.30 (1.19–4.46) 15 3.82 (1.59–9.18) 48 2.07 (1.05–4.10)
His/His (AA) 0 0 - 0 - 0 - 0 -
XRCC1Arg399Gln
Arg/Arg (GG) 119 39 1a 326 1a 82 1a 244 1a
Arg/Gln (GA) 159 51 0.87 (0.43–1.78) 371 0.74 (0.54–1.01) 79 0.59 (0.37–0.94) 292 0.79 (0.57–1.09)
Gln/Gln (AA) 54 16 1.05 (0.40–2.75) 130 0.93 (0.61–1.42) 28 0.73 (0.39–1.37) 102 0.97 (0.62–1.51)
Arg/Gln + Gln/Gln 213 67 0.91 (0.47–1.79) 500 0.78 (0.59–1.05) 107 0.62 (0.41–0.96) 394 0.83 (0.61–1.13)
XRCC3 Thr241Met
Thr/Thr (CC) 116 45 1a 324 1a 70 1a 254 1a
Thr/Met (CT) 169 48 1.18 (0.57–2.42) 380 0.83 (0.61–1.14) 91 1.06 (0.67–1.68) 289 0.78 (0.57–1.08)
Met/Met (TT) 47 13 1.29 (0.45–3.69) 123 1.03 (0.66–1.60) 28 1.25 (0.65–2.39) 95 1.01 (0.64–1.59)
Thr/Met + Met/Met 216 61 1.20 (0.60–2.39) 502 0.88 (0.65–1.18) 119 1.10 (0.71–1.71) 384 0.83 (0.61–1.13)
XPD Lys751Gln
Lys/Lys (AA) 148 43 1a 300 1a 69 1a 231 1a
Lys/Gln (AC) 142 47 0.81 (0.40–1.67) 390 1.35 (0.99–1.83) 86 1.27 (0.81–2.01) 304 1.33 (0.97–1.84)
Gln/Gln (CC) 41 15 1.00 (0.38–2.62) 136 1.66 (1.07–2.58) 34 1.59 (0.85–2.99) 102 1.61 (1.02–2.54)
Lys/Gln + Gln/Gln 183 62 0.86 (0.44–1.68) 526 1.42 (1.06–1.89) 120 1.35 (0.88–2.06) 406 1.40 (1.03–1.89)
Missing 1 1 1
a The genotype served as reference categoryPage 5 of 9
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increased risk of adenomas with OR of 2.30 (95% CI
1.19–4.46) (OR 3.82, 95% CI 1.59–9.18 and OR 2.07, 95
% CI 1.05–4.10 for high- and low-risk adenomas, respec-
tively). Among the carcinoma cases the same trend was
observed although not significant. The XRCC1 399Gln
allele showed a trend towards risk reduction for carcino-
mas and adenomas, reaching statistical significance only
for the high-risk adenomas, OR of 0.62 (95% CI 0.41–
0.96). There was no significant association between
XRCC1 194Trp allele and risk of colorectal adenomas and
carcinomas. The combination of the XRCC1 codon 280
and XRCC1 codon 399 polymorphisms showed a signifi-
cant positive association for carriers of the XRCC1 codon
280 variant allele and XRCC1 codon 399 wild type allele,
in the high-risk adenomas only, OR of 2.92 (95 % CI
1.20–7.10).
No significant association was found between the XRCC3
Thr241Met polymorphism and risk of colorectal adenomas
and carcinomas.
Further, no significant association was found between the
XPD Lys751Gln polymorphism and colorectal cancer.
There was, however, a significant association between the
XPD 751Gln allele and risk of adenomas with OR of 1.42
(95% CI 1.06–1.89). This association was limited to the
low-risk adenoma group OR of 1.40 (95% CI 1.03–1.89).
No statistical significant associations were found between
the haplotypes estimated in the XRCC1 gene and ade-
noma or carcinoma risk (further data not shown).
Discussion
In this case-control study we investigated the role of poly-
morphisms, that result in amino acid substitution, of
three DNA repair genes involved in NER, BER and HRR.
In this study we did not find an association between the
XPD Lys751Gln polymorphism and colorectal carcinoma,
but we did find an association between the XPD 751Gln
allele and colorectal adenomas, especially with the low-
risk adenomas (OR 1.40, 95 % CI 1.03–1.89). Lack of
association with the cancer group and the high-risk ade-
noma group, may be due to small sample size. Another
explanation for the observed association in the low-risk
adenoma group could be that the polymorphism may
play a role in regression of adenomas rather than progres-
sion to high-risk adenomas and cancer (advanced neopla-
sia). Although, it is generally assumed that adenomas
grow into cancer or remain in the colon until death, epi-
demiological data suggests that less than 5 % of adenomas
may progress to carcinoma in a lifetime and spontaneous
regression of adenomas has been reported [[39-41]]. Hof-
stad et al. [40] have reported that 60 % of adenomas with
diameters less than 10 mm stop growing or go into regres-
sion within 3 years of observation. In our material, 63 %
of cases with low-risk adenomas were hetero- or
homozygous for this polymorphism. However, the char-
Table 5: Combinations of XRCC1 Arg280His and XRCC1 Arg399Gln polymorphisms and risk of colorectal carcinomas and adenomas. 
ORs are adjusted for age.
Case group OR (95 % CI) (N case/N controls)
XRCC1 Arg399Gln XRCC1 Arg280His
Carcinomas GG GA
GG 1.0a (56/137) 1.93 (0.44–8.49) (7/11)
GA 0.76 (0.41–1.38) (65/180) 1.18 (0.20–7.02) (5/7)
AA 0.96 (0.44–2.09) (24/64) -
Adenomas GG GA
GG 1.0a (341/137) 1.75 (0.85–3.63) (50/11)
GA 0.85 (0.64–1.13) (415/180) 1.22 (0.50–3.00) (27/7)
AA 0.93 (0.44–1.36) (149/64) -
High-risk adenomas GG GA
GG 1.0a (83/137) 2.92 (1.20–7.10) (17/11)
GA 0.77 (0.51–1.15) (92/180) 0.63 (0.14–2.71) (3/7)
AA 0.74 (0.42–1.29) (32/64) -
Low-risk adenomas GG GA
GG 1.0a (258/137) 1.43 (0.66–3.09) (33/11)
GA 0.88 (0.65–1.18) (324/180) 1.47 (0.59–3.66) (24/7)
AA 1.00 (0.67–1.48) (117/64)
a The genotype served as a reference categoryPage 6 of 9
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known.
Our results indicate that the XPD Lys751Gln polymor-
phism may predispose slightly to development of colorec-
tal adenomas or that the polymorphism may be of
importance for arresting the adenoma-carcinoma
sequence in the low-risk phase and facilitate regression of
adenomas. Large prospective studies would be required to
clarify this issue. XPD polymorphisms have been analyzed
particularly in epidemiological studies on skin and smok-
ing-related cancers and no obvious relationship has been
found for these types of cancers. Mort et al. [14] and Yeh
et al. [15] have reported no significant association
between the XPD Lys751Gln polymorphism and colorectal
cancer. To our knowledge no studies have been published
on the association between XPD polymorphisms and
colorectal adenomas.
We found no significant association between the XRCC1
194Trp allele and colorectal adenoma or carcinoma risk.
This is not in agreement with the results reported by
Abdel-Rahman et al. [12], but consistent with the results
reported by Hong et al. [13].
In our study, the XRCC1 399Gln allele was associated
with a slightly decreased risk of colorectal adenomas and
carcinomas, although statistically significant only for the
high-risk adenomas, (OR 0.62, 95% CI 0.41–0.96). This
protective role of the XRCC1 399Gln allele is in contrast
to previous reports [12,13] on this BER gene polymor-
phism and colorectal cancer risk. Previously, we reported
a reduced risk of colorectal adenomas and cancer in asso-
ciation with another BER gene polymorphism, the OGG1
Ser326Cys [42]. We have therefore tested the XRCC1 codon
399 and OGG1 codon 326 variant alleles in combination,
but it showed no significant association with colorectal
adenoma or cancer risk (OR 1.18, 95% CI 0.38–3.68; OR
0.91, 95% CI 0.54–1.52) (further data not shown).
In this study we identified an association between the
XRCC1 280His allele and risk of colorectal adenomas and
carcinomas, but again, this increased risk was only signif-
icant for the adenomas (OR 2.30, 95% CI 1.19–4.46). As
far as we know, the KAM study is the first reporting an
association between the XRCC1 Arg280His polymorphism
and colorectal adenoma and carcinoma risk. There are few
reports on this polymorphism. In 1999, Lunn et al. [43]
examined the relationship of XRCC1 genotypes and dif-
ferent levels of aflatoxin B1-DNA adducts (51 controls
and 69 cases), but no significant effects were observed for
the XRCC1 280His allele. Recently, Hong et al. [13]
reported an association between the 280His allele and
colorectal cancer in combination with the 194Arg allele
and the 399Arg allele (OR 1.78, 95 % CI 1.09–2.89).
Takanami et al. [44] have reported results suggesting that
the XRCC1 Arg280His variant protein has an ineffective or
reduced ability to localize a damaged site in the chromo-
some, thereby reducing the cellular BER/SSB repair effi-
ciency. The variant 280His allele may allow un-repaired
SSBs to accumulate, thereby accelerating genomic insta-
bility which consequently increases the risk of carcinogen-
esis. This is supported by our findings of an association
between a variant 280His allele and high-risk adenomas.
We found that the two polymorphisms XRCC1 Arg280His
and XRCC1 Arg399Gln were linked such that the variant
allele of XRCC1 codon 280 co-segregated with the wild
type allele of XRCC1 codon 399 (p = 0.045). When the
XRCC1 Arg280His and XRCC1 Arg399Gln polymor-
phisms were combined, the effects of the polymorphisms
appeared independently of each other. The variant carriers
of XRCC1 codon 399 were not statistically significantly,
but consistently, at decreased risk of cancer, whereas
XRCC1 codon 280 heterozygotes were at increased risk of
cancer.
No significant association was found between the XRCC3
Thr241Met polymorphism and colorectal adenomas or
carcinomas in our study. This XRCC3 codon 241 poly-
morphism has previously shown a significant association
with colorectal cancer risk [14] (OR 1.52, 95% CI 1.04–
2.22) while in another study no association was detected
[15]. One study reports no association between this
XRCC3 polymorphism and colorectal adenoma risk [45].
High alcohol consumption has been linked to increased
risk of colorectal neoplasia caused by an antifolate effect,
resulting in uracil misincorporation into DNA and chro-
mosomal breaks [46].
We have tested the combination of the XRCC3 codon 241
variant allele and alcohol consumption but it showed no
significant association with colorectal adenoma or carci-
noma risk (OR 1.00, 95% CI 0.98–1.02; OR 0.96, 95% CI
0.92–1.00) (further data not shown). We have also tested
the interaction between each of the five DNA repair poly-
morphisms and cigarette smoking, but they showed no
significant association with colorectal adenoma or carci-
noma (further data not shown). These results are in agree-
ment with other published studies [45,47]. To the best of
our knowledge, contrary to genetic factors such as meta-
bolic genetic polymorphisms, few studies suggest that the
genetic polymorphisms of DNA repair genes may interact
with environmental factors such as alcohol drinking and
cigarette smoking [3,9].
The divergence in results from different studies on XRCC1,
XRCC3 and XPD polymorphisms may be related to varia-
tion in carcinogenic exposure and ethnic origin of the
studied populations. Too small sample size and/or the
inadequate controlling for certain confounders such asPage 7 of 9
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may contribute to differing results. It is possible that some
of the candidate genes only contribute to colorectal cancer
development in combination with certain dietary and /or
lifestyle factors. Interaction between various gene prod-
ucts may increase cancer risk. A combination of polymor-
phisms in these genes may have additive or synergistic
effects. For polymorphisms not showing an obvious asso-
ciation with colorectal adenoma or cancer when studied
separately, an association with colorectal adenoma or can-
cer is still possible in combination with other polymor-
phisms. We have tested the combination of the three
polymorphisms in the XRCC1 gene but none of the esti-
mated haplotypes showed a significant association with
colorectal adenoma or carcinoma risk.
The design of this study is relatively strong because the
controls were recruited from the same cohort as the ade-
noma and carcinoma cases. The CRC cases and controls
have not been matched by age which may affect the results
in a study. However, our controls have been screened and
found polyp free and the risk of any of them having colon
cancer at the time of inclusion is not very likely. The defi-
nition of polyp-free controls was based on a negative flex-
ible sigmoidoscopy screening examination. It has been
estimated that the risk of erroneously classifying individ-
uals with proximal advanced neoplasia as neoplasia-free
is less than 3 % at flexible sigmoidoscopy [48,49]. There-
fore, the risk of misclassification appears small, and it may
only contribute to a type II statistical error, reducing the
difference between case groups and controls. It cannot be
excluded that the present findings are due to chance. The
relatively small numbers of the CRC cases, and the low
frequency of the variant allele for at least some of the pol-
ymorphisms limited our power to detect an assosiation
with risk of adenomas and carcinomas.
Conclusion
In conclusion, our results suggest an increased risk for
advanced colorectal neoplasia in individuals with XRCC1
Arg280His polymorphism and a reduced risk for persons
with XRCC1 Arg399Gln. The increased risk of having low-
risk adenomas in contrast to advanced neoplasia for indi-
viduals with XPD Lys751Gln polymorphism may suggest a
role in regression of adenomas and should be explored in
prospective studies of in situ adenomas.
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